Stuart Weiss, MD
Endocrinology, Diabetes & Metabolism · New York, NYNPI 1275568990
Payments from drug & device makers
Across 1,279 payments — averaging $221.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$200K
- Novo Nordisk$38K
- AstraZeneca$10K
- Johnson & Johnson$8K
- Eli Lilly$7K
- Mannkind Corporation$7K
- plus $12K from 38 others
Across 1 payment — averaging $97.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$97
What the payments were for
- Consulting fees$7,9253%
- Speaking & faculty fees$217,77179%
- Travel & lodging$23,4759%
- Food & beverage$26,1219%
- Education$970%
- Other$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRULICITY$98,254
- MOUNJARO$34,582
- LYUMJEV$31,988
- Tresiba$12,163
- FARXIGA$9,652
- RYBELSUS$8,279
- INVOKANA$8,161
- Ozempic$8,013
- AFREZZA$6,543
- Xultophy 100/3.6$3,998
- iLet Bionic Pancreas$819
- TEPEZZA$391
- Korlym$318
- Omnipod$275
- iLet Insulin Infusion Kit Inset$273
- iLet Insulin Infusion Kit Contact Detach$273
- Kerendia$234
- CeQur Simplicity$208
- DEXCOM G7 GSS (161)$170
- Pogo Automatic Blood Glucose Monitoring System$151
How this compares
$282,711 in reported general payments places this provider in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 396 | $610,722 |
| JardianceEmpagliflozin | 564 | $605,131 |
| MounjaroTirzepatide | 337 | $495,742 |
| FarxigaDapagliflozin Propanediol | 187 | $195,773 |
| TrulicityDulaglutide | 85 | $138,309 |
| RybelsusSemaglutide | 66 | $118,158 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 56 | $48,377 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 24 | $48,336 |
| AfrezzaInsulin Regular, Human | 14 | $38,466 |
| JanuviaSitagliptin Phosphate | 36 | $32,128 |
| TradjentaLinagliptin | 36 | $25,617 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 22 | $24,244 |
| Tresiba Flextouch U-100Insulin Degludec | 42 | $23,824 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 23 | $21,854 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 19 | $19,705 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $37,912 | $733,446473 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $945 | $654,992622 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $200,385 | $638,875437 claims |
| AstraZenecaFarxiga | $10,080 | $195,773187 claims |
| MerckJanumet Xr, Januvia, Janumet, Steglatro | $795 | $106,033126 claims |
| Mannkind CorporationAfrezza | $7,159 | $38,46614 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,459 | $19,70519 claims |
| Johnson & JohnsonInvokana | $8,132 | $16,96815 claims |
| AbbVieSynthroid | $1,239 | $4,85765 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $90 | $3,131196 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in New York
- Anastasios ManessisNew York$4.4M
- Adi CohenNew York$2.5M
- Carol LevyNew York$2.2M
- Mishaela RubinNew York$2M
- Henry GinsbergNew York$1M
- John BilezikianNew York$814K
- Eliza GeerNew York$760K
- Christoph BuettnerNew York$709K
- Emily SteinNew York$489K
- Jason BakerNew York$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.